The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model

The hexosamine biosynthetic pathway (HBP) is essential for the production of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the building block of glycosaminoglycans, thus playing a crucial role in cartilage anabolism. Although O-GlcNAcylation represents a protective regulatory mechanism in ce...

Full description

Bibliographic Details
Main Authors: Jana Riegger, Julia Baumert, Frank Zaucke, Rolf E. Brenner
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/22/14/7247
id doaj-b0847e7a3bed4102b0a9be521cf46f2c
record_format Article
spelling doaj-b0847e7a3bed4102b0a9be521cf46f2c2021-07-23T13:45:09ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-01227247724710.3390/ijms22147247The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo ModelJana Riegger0Julia Baumert1Frank Zaucke2Rolf E. Brenner3Division for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, 89081 Ulm, GermanyDivision for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, 89081 Ulm, GermanyDr. Rolf M. Schwiete Research Unit for Osteoarthritis, Department of Orthopaedics (Friedrichsheim), University Hospital Frankfurt, Goethe University, 60528 Frankfurt/Main, GermanyDivision for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, 89081 Ulm, GermanyThe hexosamine biosynthetic pathway (HBP) is essential for the production of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the building block of glycosaminoglycans, thus playing a crucial role in cartilage anabolism. Although O-GlcNAcylation represents a protective regulatory mechanism in cellular processes, it has been associated with degenerative diseases, including osteoarthritis (OA). The present study focuses on HBP-related processes as potential therapeutic targets after cartilage trauma. Human cartilage explants were traumatized and treated with GlcNAc or glucosamine sulfate (GS); PUGNAc, an inhibitor of O-GlcNAcase; or azaserine (AZA), an inhibitor of GFAT-1. After 7 days, cell viability and gene expression analysis of anabolic and catabolic markers, as well as HBP-related enzymes, were performed. Moreover, expression of catabolic enzymes and type II collagen (COL2) biosynthesis were determined. Proteoglycan content was assessed after 14 days. Cartilage trauma led to a dysbalanced expression of different HBP-related enzymes, comparable to the situation in highly degenerated tissue. While GlcNAc and PUGNAc resulted in significant cell protection after trauma, only PUGNAc increased COL2 biosynthesis. Moreover, PUGNAc and both glucosamine derivatives had anti-catabolic effects. In contrast, AZA increased catabolic processes. Overall, “fueling” the HBP by means of glucosamine derivatives or inhibition of deglycosylation turned out as cells and chondroprotectives after cartilage trauma.https://www.mdpi.com/1422-0067/22/14/7247hexosamine biosynthetic pathwaycartilage traumapost-traumatic osteoarthritischondrocytesO-GlcNAcylationglucosamine
collection DOAJ
language English
format Article
sources DOAJ
author Jana Riegger
Julia Baumert
Frank Zaucke
Rolf E. Brenner
spellingShingle Jana Riegger
Julia Baumert
Frank Zaucke
Rolf E. Brenner
The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model
International Journal of Molecular Sciences
hexosamine biosynthetic pathway
cartilage trauma
post-traumatic osteoarthritis
chondrocytes
O-GlcNAcylation
glucosamine
author_facet Jana Riegger
Julia Baumert
Frank Zaucke
Rolf E. Brenner
author_sort Jana Riegger
title The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model
title_short The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model
title_full The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model
title_fullStr The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model
title_full_unstemmed The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model
title_sort hexosamine biosynthetic pathway as a therapeutic target after cartilage trauma: modification of chondrocyte survival and metabolism by glucosamine derivatives and pugnac in an ex vivo model
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-07-01
description The hexosamine biosynthetic pathway (HBP) is essential for the production of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the building block of glycosaminoglycans, thus playing a crucial role in cartilage anabolism. Although O-GlcNAcylation represents a protective regulatory mechanism in cellular processes, it has been associated with degenerative diseases, including osteoarthritis (OA). The present study focuses on HBP-related processes as potential therapeutic targets after cartilage trauma. Human cartilage explants were traumatized and treated with GlcNAc or glucosamine sulfate (GS); PUGNAc, an inhibitor of O-GlcNAcase; or azaserine (AZA), an inhibitor of GFAT-1. After 7 days, cell viability and gene expression analysis of anabolic and catabolic markers, as well as HBP-related enzymes, were performed. Moreover, expression of catabolic enzymes and type II collagen (COL2) biosynthesis were determined. Proteoglycan content was assessed after 14 days. Cartilage trauma led to a dysbalanced expression of different HBP-related enzymes, comparable to the situation in highly degenerated tissue. While GlcNAc and PUGNAc resulted in significant cell protection after trauma, only PUGNAc increased COL2 biosynthesis. Moreover, PUGNAc and both glucosamine derivatives had anti-catabolic effects. In contrast, AZA increased catabolic processes. Overall, “fueling” the HBP by means of glucosamine derivatives or inhibition of deglycosylation turned out as cells and chondroprotectives after cartilage trauma.
topic hexosamine biosynthetic pathway
cartilage trauma
post-traumatic osteoarthritis
chondrocytes
O-GlcNAcylation
glucosamine
url https://www.mdpi.com/1422-0067/22/14/7247
work_keys_str_mv AT janariegger thehexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel
AT juliabaumert thehexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel
AT frankzaucke thehexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel
AT rolfebrenner thehexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel
AT janariegger hexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel
AT juliabaumert hexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel
AT frankzaucke hexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel
AT rolfebrenner hexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel
_version_ 1721287937115553792